Recent Updates
Recently added Catalysts

ACCG-2671

Phase 1

Obesity | Small molecule | Metabolic |Structure Therapeutics Inc.|Trials Updated: Sep 14, 2026

ACCG-2671 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2026

ACCG-2671 target and mechanism

Molecular targetamylin receptor
Target classReceptor
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment164

FDA Designations

No designations recorded

ACCG-2671 clinical trials

ACCG-2671 · 1 trial · 1 indication

Phase 1 1
NCT07815678First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671Obesity
RECRUITING164 Analytics
PHASE1RECRUITING
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Obesity
NCT07815678164
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with one or more adverse events (AEs) as assessed by CTCAE v5.0
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Number of participants with one or more serious adverse advents (SAEs) as assessed by CTCAE v5.0
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Number of participants with one or more treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0
Baseline to Day 21 (Part 2)
Change from baseline in systolic blood pressure
Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in diastolic blood pressure
Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in heart rate
Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in ECG ventricular heart rate
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)
Change from baseline in ECG PR interval
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)
Change from baseline ECG QRS duration
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)
Change from baseline in ECG QT Interval corrected using Fridericia's Formula (QTcF)
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)
Change from baseline in hemoglobin
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in hematocrit
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in thrombocyte count (platelet count)
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in white blood cell (WBC) count
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in prothrombin time
Baseline to day 17 (Part 1, Cohorts 1, 2, and 3); baseline to day 22 (Part 1, Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3)
Change from baseline in international normalized ratio (INR)
Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to day 22 (Part 1 Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3)
Change from baseline in activated partial thromboplastin time (aPTT)
Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in fibrinogen activity
Baseline to Day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in sodium
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in potassium
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in chloride
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in phosphate
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in calcium
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in glucose
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in amylase
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in lipase
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in magnesium
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in albumin
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in lactate dehydrogenase (LDH)
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in creatine kinase
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in creatinine
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in blood urea nitrogen
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in alanine aminotransferase (ALT)
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in total alkaline phosphatase
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in aspartate aminotransferase (AST)
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in gamma-glutamyl transferase (GGT)
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in total bilirubin
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in direct bilirubin
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Change from baseline in indirect bilirubin
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)
Number of participants with abnormal urinalysis parameters
Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in urinalysis (Including pH, specific gravity, glucose, protein, ketones, blood, nitrites, urobilinogen, and leukocyte esterase)

Secondary Endpoints

Maximum observed plasma concentration (Cmax) of ACCG-2671
Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of ACCG-2671
Predose through Day 22 (Part 1); predose through Day 18 (Part 2)
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) of ACCG-2671
Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1 (SAD)EXPERIMENTALAscending doses of ACCG-2671 administered orally in healthy participants
Placebo Part 1 (SAD)PLACEBO_COMPARATORAdministered orally in healthy participants
Part 2 (Food-effect)EXPERIMENTALSingle low dose of ACCG-2671 administered orally in healthy participants under fasted and fed state
ACCG-2671 Part 3 (MAD)EXPERIMENTALEscalating doses of ACCG-2671 administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)
Placebo Part 3 (MAD)PLACEBO_COMPARATORPlacebo administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)

Interventions

NameTypeDescription
ACCG-2671DRUGAdministered orally
PlaceboDRUGAdministered orally
Unlock Study Design Details

Eligibility Criteria

Age Range25 Years to 75 Years
SexALL
Healthy VolunteersYes
Study Sites6

Inclusion Criteria: * Signed informed consent * Men and women with the following at the time of Screening for Part 1 and 2: ≥25 years and ≤65 years of age and BMI ≥18.0 kg/m2 and \<30.0 kg/m2 * For Part 3, ≥25 years and ≤75 years of age and BMI ≥30.0 kg/m2 * For Part 3, receiving a stable dose of a...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Obesity 301 trials

Top 20 of 35 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN8PHASE3Elecoglipron, Lenbelintide, AZD6234, AZD9550, AZD1043
Amgen Inc.AMGN11PHASE3Maridebart cafraglutide
Pfizer Inc.PFE12PHASE3Berobenatide, PF-08653945, PF-08642534
Eli Lilly and CompanyLLY46PHASE3Orforglipron, Tirzepatide, Retatrutide, Eloralintide, Mirikizumab
Novo Nordisk A/S Sponsored ADR Class BNVO71PHASE3Cagrilintide, Semaglutide, Liraglutide, CagriSema, NNC0487-0111
Regeneron Pharmaceuticals, Inc.REGN5PHASE3mibavademab, Trevogrumab, Garetosmab, Olatorepatide, REGN20934
Structure Therapeutics, Inc. Sponsored ADRGPCR5PHASE3Aleniglipron, ACCG-2671
Rhythm Pharmaceuticals, Inc.RYTM6PHASE3Setmelanotide, Bivamelagon, RM-718
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
Kailera Therapeutics, Inc.KLRA5PHASE3Ribupatide (KAI-9531), KAI-7535
Hoffmann-La RocheRHHBY11PHASE3Enicepatide, Petrelintide, RO7204239, RO7795081
AbbVie, Inc.ABBV2PHASE2ABBV-295
PfizerMTSR3PHASE3MET097, MET233
Biohaven Ltd.BHVN1PHASE2Taldefgrobep Alfa
Skye Bioscience, Inc.SKYE1PHASE2Nimacimab
Palatin Technologies, Inc.PTN1PHASE2bremelanotide
Veru IncVERU1PHASE2Enobosarm
Alnylam Pharmaceuticals, IncALNY2PHASE1ALN-2232, ALN-6222
Arrowhead Pharmaceuticals, Inc.ARWR2PHASE1ARO-INHBE, ARO-ALK7
Gilead Sciences, Inc.GILD1PHASE1GS-4571
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWSep 15, 2026NCT07815678lastUpdatePostDate: changed
LOWSep 15, 2026NCT07815678lastUpdatePostDate: changed
LOWSep 15, 2026NCT07815678lastUpdatePostDate: changed
LOWSep 11, 2026NCT07815678NEW_TRIAL: changed
LOWSep 11, 2026NCT07815678NEW_TRIAL: changed

Frequently asked questions about ACCG-2671

What is ACCG-2671?

ACCG-2671 is an investigational small molecule drug being developed by Structure Therapeutics Inc. for obesity. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is designed to act on the amylin receptor, a metabolic target being explored for weight management.

What is ACCG-2671 used for?

ACCG-2671 is being studied for the treatment of obesity. It is an investigational therapy and has not been approved for any indication. The ongoing Phase 1 trial enrolls adults with obesity to evaluate the drug's safety, tolerability, pharmacokinetics, and food effect.

What does ACCG-2671 target?

ACCG-2671 targets the amylin receptor. It is a small molecule designed to interact with this receptor, which is part of the metabolic signaling pathways involved in appetite and weight regulation. Targeting the amylin receptor is an approach being investigated for obesity treatment.

Who is developing ACCG-2671?

ACCG-2671 is being developed by Structure Therapeutics Inc., which trades under the ticker GPCR. The company is advancing the drug as an investigational small molecule for obesity, with a Phase 1 first-in-human study currently recruiting participants.

What phase is ACCG-2671 in?

ACCG-2671 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 program includes one active trial that is currently recruiting, with no completed trials to date.

What clinical trials is ACCG-2671 in?

ACCG-2671 is being evaluated in a first-in-human Phase 1 trial, NCT07815678, titled First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671. The trial is recruiting 164 participants with obesity in the United States. It is randomized, double-blind, and placebo-controlled.

Other drugs targeting amylin receptor

LY3841136 LLY· PHASE2 VK3019 VKTX· PHASE1

Explore more on BiopharmaWatch

Structure Therapeutics Inc. (GPCR)Pipeline, catalysts, financials, insiders and newsObesity disease mapEvery company developing for Obesity, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track